Prizlon-cel Moves Into a Harder Post-CAR T Setting in Large B-Cell Lymphoma
A new phase 2 study is set to test Prizloncabtagene Autoleucel, or Prizlon-cel, in one of the most treatment-resistant corners of aggressive lymphoma care: relapsed or refractory large B-cell lymphoma after prior FDA-approved CAR T-cell therapy. The protocol places the product squarely in a population with few remaining options, where antigen escape, T-cell exhaustion, and clonal evolution often blunt the durability of earlier cellular therapy.
The trial is multicenter, open-label, and single-arm. Roughly 55 adults are expected to enroll, with approximately 50 to undergo leukapheresis, lymphodepleting chemotherapy, and a single infusion of the investigational product. Follow-up for efficacy, safety, persistence, pharmacokinetics, pharmacodynamics, and biomarker analysis extends for 24 months, while long-term gene therapy-related safety surveillance continues for up to 15 years after infusion.
Dual CD19/CD20 Targeting Aims to Address Antigen Escape
The biologic logic behind Prizlon-cel is straightforward. Standard CD19-directed CAR T-cell therapy has transformed the management of aggressive B-cell lymphomas, but relapse after initial response remains a major clinical problem. Loss or downregulation of CD19 is one plausible mechanism of resistance. By directing the engineered T cells against both CD19 and CD20, the construct is designed to reduce the chance that a single antigen-loss event will leave the tumor invisible to immune attack.
This matters in diffuse large B-cell lymphoma and closely related entities because these diseases are biologically heterogeneous. The trial includes diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements, high-grade B-cell lymphoma not otherwise specified, and follicular large B-cell lymphoma. In practice, these are all aggressive B-cell neoplasms with enough clinical overlap to justify a shared cellular strategy, but enough genomic and phenotypic diversity to make immune escape a serious concern.
A single antigen target can be a narrow gate. Two targets widen the path, but do not remove the risk of resistance altogether.
Eligibility Focuses on Heavily Pretreated Adults With Measurable Disease
The inclusion criteria describe a population already shaped by multiple lines of therapy. Participants must be at least 18 years old, able to provide informed consent, and have B-cell non-Hodgkin lymphoma consistent with the listed 2022 WHO-defined diagnoses. Disease must be relapsed or refractory after at least two lines of standard therapy, including prior FDA-approved commercially available CAR T-cell therapy, with at least three months elapsed since that previous CAR T exposure.
Measurable disease under the Lugano 2014 classification is required, which is important because the primary efficacy endpoint is overall response rate, with complete and partial responses measured through month 24. The trial also excludes prior allogeneic hematopoietic stem cell transplantation, autologous stem cell transplant within 12 weeks of leukapheresis, and any previous investigational CAR T-cell therapy.
Those exclusions are not minor administrative details. They select for patients who can safely undergo a second cellular therapy course without the confounding biology of a recent transplant or an experimental CAR platform layered on top of prior immune manipulation. In a setting where marrow reserve, inflammatory risk, and prior treatment intensity can shape outcomes as much as tumor biology, the eligibility rules define the practical limits of the study population.
Safety Will Be Judged Alongside Response, Not After It
The primary endpoint bundle includes adverse event incidence and severity, assessed through month 24 and graded by NCI CTCAE Version 6.0. That places safety on equal footing with efficacy from the outset, which is appropriate for a CAR T-cell program in a heavily pretreated lymphoma cohort. The study is not masking treatment assignment, so toxicity monitoring will depend on direct clinical observation rather than comparative blinding.
That matters because cellular therapies bring a familiar but serious toxicity profile into the clinic: cytokine-driven inflammatory effects, cytopenias, infection risk, and the possibility of delayed complications related to persistence of engineered cells. The protocol does not spell out specific toxicity syndromes in the provided record, but the long follow-up window and gene therapy surveillance period indicate an awareness that CAR T-cell therapy requires watching for both early and late adverse consequences.
The study also measures time to response, duration of response, best overall response, progression-free survival, and overall survival. Those secondary endpoints should help separate a transient tumor flare from a durable remission. In aggressive lymphoma, early shrinkage is encouraging; persistence of response is what changes practice.
Persistence Biomarkers Will Test Whether the Cells Stay in the Fight
Beyond standard clinical endpoints, the protocol includes several translational readouts. Investigators will use quantitative PCR to estimate maximum plasma concentration after infusion and employ flow cytometry to characterize CAR T-cell expansion and persistence through area under the curve measurements in peripheral blood. Peripheral blood CD19/CD20-positive cell changes are also scheduled for assessment.
These measures are more than laboratory bookkeeping. In CAR T-cell therapy, expansion kinetics often track with biologic potency, while persistence can hint at how long immune surveillance might continue after the first response. If Prizlon-cel expands robustly and persists, that would support the premise that dual targeting can maintain pressure on residual lymphoma cells after prior CD19-directed treatment has failed. If expansion is poor or short-lived, the failure mode may be pharmacologic rather than antigenic.
The planned biomarker work should also help clarify whether peripheral antigen changes reflect deeper tumor clearance or simply transient circulation effects. In a disease where tumor burden can shift quickly, molecular signals may offer earlier clues than serial imaging alone.
A Small Cohort, a Narrow Question, and a Long Horizon
The estimated start date is May 2027, with primary completion projected for June 2029 and final study completion in December 2030. The record lists AbelZeta Inc. as sponsor, with Yihong Yao, PhD, serving as study director. Study sites are listed in Gilbert, Arizona, and La Jolla, California.
This is not a definitive registration for a practice-changing approval. It is an early test of whether a dual-target autologous CAR T-cell product can salvage patients whose disease has already defeated one of the field’s biggest therapeutic advances. The question is sharp, and the answer will depend on whether response rates, durability, and safety converge in a post-CAR T population that has already proven difficult to treat.
If the study delivers meaningful activity, it would support the broader biologic case for multiplex antigen targeting in lymphoma. If it does not, the results will still be informative, because the failure will likely expose where the current CAR T paradigm breaks down in the second line of cellular retreatment and how much of that problem is driven by tumor escape rather than patient-specific immune exhaustion or prior treatment history.